Distinct and Shared Risk Profiles for Suicide Attempt Versus Suicide: Insights from Danish Registers and Genomic Data
Posted innews Psychiatry Public Health

Distinct and Shared Risk Profiles for Suicide Attempt Versus Suicide: Insights from Danish Registers and Genomic Data

A large Danish register and genetic study shows overlapping but distinct environmental and genetic risk factors for nonfatal suicide attempts and death by suicide, with chronic and functional health problems linked more to attempts and severe somatic illness and psychopathology-related genetics more to suicide.
Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery
Posted inDermatology news Psychiatry

Intimacy, Intranasal Oxytocin, and Faster Wound Healing: A Randomized Trial Linking Touch, Sex, and Neuroendocrine Recovery

A double‑blind RCT in 160 healthy adults found that intranasal oxytocin combined with structured positive interaction and daily physical intimacy (affectionate touch, sex) was associated with reduced cortisol and modestly faster dermatologic wound healing, with caveats on robustness and generalizability.
Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Posted inCardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.
Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS
Posted inDiabetes & Endocrinology news

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promising but require randomized, biomarker‑driven studies to define metabolic and reproductive benefits and safety in this population.
Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Posted inClinical Updates news OB/GYN & Women's Health

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.
Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
Posted innews OB/GYN & Women's Health

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.